Abstract
20 years have passed since the discovery of the major breast cancer susceptibility gene, BRCA1. Extraordinary progress has been made in the understanding of how BRCA1 and its associated proteins function, and the clinical consequences of malfunctioning BRCA proteins are now evident.1,2 The initial concerns3 about the risks of genetic testing for women carrying mutations in BRCA1 and BRCA2 seem to have receded. Moreover, the recent ruling by the US Supreme Court that genes are not patentable has opened up the genetic testing field, at least in the USA, in an unprecedented manner.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
